408 related articles for article (PubMed ID: 30166303)
1. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
Connick P; De Angelis F; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S; Chataway J;
BMJ Open; 2018 Aug; 8(8):e021944. PubMed ID: 30166303
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Fluoxetine, Riluzole and Amiloride in treating neuropathic pain associated with secondary progressive multiple sclerosis. Pre-specified analysis of the MS-SMART double-blind randomised placebo-controlled trial.
Foley P; Parker RA; de Angelis F; Connick P; Chandran S; Young C; Weir CJ; Chataway J;
Mult Scler Relat Disord; 2022 Jul; 63():103925. PubMed ID: 35671671
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.
John NA; Solanky BS; De Angelis F; Parker RA; Weir CJ; Stutters J; Carrasco FP; Schneider T; Doshi A; Calvi A; Williams T; Plantone D; Monteverdi A; MacManus D; Marshall I; Barkhof F; Gandini Wheeler-Kingshott CAM; Chataway J;
J Magn Reson Imaging; 2024 Jun; 59(6):2192-2201. PubMed ID: 37787109
[TBL] [Abstract][Full Text] [Related]
5. Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
Wong C; Dakin RS; Williamson J; Newton J; Steven M; Colville S; Stavrou M; Gregory JM; Elliott E; Mehta AR; Chataway J; Swingler RJ; Parker RA; Weir CJ; Stallard N; Parmar MKB; Macleod MR; Pal S; Chandran S
BMJ Open; 2022 Jul; 12(7):e064173. PubMed ID: 35798516
[TBL] [Abstract][Full Text] [Related]
6. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
7. NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study.
Solanky BS; John NA; DeAngelis F; Stutters J; Prados F; Schneider T; Parker RA; Weir CJ; Monteverdi A; Plantone D; Doshi A; MacManus D; Marshall I; Barkhof F; Gandini Wheeler-Kingshott CAM; Chataway J;
AJNR Am J Neuroradiol; 2020 Dec; 41(12):2209-2218. PubMed ID: 33154071
[TBL] [Abstract][Full Text] [Related]
8. Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial.
Cambron M; Mostert J; Haentjens P; D'Hooghe M; Nagels G; Willekens B; Heersema D; Debruyne J; Van Hecke W; Algoed L; De Klippel N; Fosselle E; Laureys G; Merckx H; Van Wijmeersch B; Vanopdenbosch L; Verhagen W; Hupperts R; Hengstman G; Michiels V; Van Merhaegen-Wieleman A; De Keyser J
Trials; 2014 Jan; 15():37. PubMed ID: 24460863
[TBL] [Abstract][Full Text] [Related]
9. Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
McKee JB; Elston J; Evangelou N; Gerry S; Fugger L; Kennard C; Kong Y; Palace J; Craner M
BMJ Open; 2015 Nov; 5(11):e009200. PubMed ID: 26553836
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
11. Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Arun T; Tomassini V; Sbardella E; de Ruiter MB; Matthews L; Leite MI; Gelineau-Morel R; Cavey A; Vergo S; Craner M; Fugger L; Rovira A; Jenkinson M; Palace J
Brain; 2013 Jan; 136(Pt 1):106-15. PubMed ID: 23365093
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial.
Cambron M; Mostert J; D'Hooghe M; Nagels G; Willekens B; Debruyne J; Algoed L; Verhagen W; Hupperts R; Heersema D; De Keyser J;
Mult Scler; 2019 Nov; 25(13):1728-1735. PubMed ID: 31218911
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
14. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
[TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
16. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
[TBL] [Abstract][Full Text] [Related]
17. A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial.
De Keersmaecker AV; Van Doninck E; Popescu V; Willem L; Cambron M; Laureys G; D' Haeseleer M; Bjerke M; Roelant E; Lemmerling M; D'hooghe MB; Derdelinckx J; Reynders T; Willekens B
Front Immunol; 2024; 15():1362629. PubMed ID: 38680485
[TBL] [Abstract][Full Text] [Related]
18. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
[TBL] [Abstract][Full Text] [Related]
19. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Chataway J; Schuerer N; Alsanousi A; Chan D; MacManus D; Hunter K; Anderson V; Bangham CR; Clegg S; Nielsen C; Fox NC; Wilkie D; Nicholas JM; Calder VL; Greenwood J; Frost C; Nicholas R
Lancet; 2014 Jun; 383(9936):2213-21. PubMed ID: 24655729
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
